Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has multiple ...

Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...

Scientist Stephen Krahling worked on a project at Merck called “Protocol 7” and was uniquely positioned to blow the whistle on what he learned.

A month has gone by since the last earnings report for Merck (MRK). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...

Merck (MRK) announced that the Committee for ... adults against the serotypes that cause the majority of invasive pneumococcal disease cases. If approved in the EU, it would mark the fourth ...

Her lawsuit also claims that Merck marketed the vaccine as safe while concealing knowledge of dangerous side effects. Merck has denied the claims. "Merck remains confident that it will prevail in ...

The pneumococcal vaccine can protect you from an infection caused by the bacteria Streptococcus pneumoniae or pneumococcus. (Photo Credit: Bernard Chantal/Dreamstime) Pneumococcal disease can ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

while Pneumovax 23 (pneumococcal vaccine polyvalent) vaccine sales declined 12% to $74 million. Sales of Vaxneuvance, Merck’s pneumococcal 15-valent conjugate vaccine, were $161 million ...